Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call

Tuesday, November 4, 2008 General News
Email Print This Page Comment
Font : A-A+

SEATTLE, Nov. 3 Trubion Pharmaceuticals Inc.(Nasdaq: TRBN) today announced that it plans to issue earnings results for thethird quarter and nine months ended Sept. 30, 2008, after the close of marketon Nov. 10, 2008. The company's earnings conference call will take place Nov.10, 2008, at 2 p.m. PST (5 p.m. EST).

Both live events will be available for viewing on Trubion's website athttp://investors.trubion.com/events.cfm.

Third-Quarter and Nine Months Earnings Conference Call: 2 p.m. PST/5 p.m.EST, Nov. 10, 2008

Trubion will host a conference call and webcast to discuss itsthird-quarter and nine months 2008 financial results. The call will be heldNov. 10 at 2 p.m. PST (5 p.m. EST). The live event will be available onTrubion's website at http://investors.trubion.com/events.cfm, or by calling(877) 440-5804 or (719) 325-4881. A replay of the discussion will be availablebeginning the evening of Nov. 10 on Trubion's website or by calling(888) 203-1112 or (719) 457-0820, and entering 8489656. The telephone replaywill be available through Nov. 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline ofnovel protein therapeutic product candidates to treat autoimmune andinflammatory diseases and cancer. The company's mission is to develop avariety of first-in-class and best-in-class product candidates, customized foroptimal safety, efficacy, and convenience that it believes may offer improvedpatient experiences. Trubion's current product candidates are novelsingle-chain protein, or SMIP(TM), therapeutics, and are designed using itscustom drug assembly technology. Trubion's product pipeline includesCD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune andinflammatory diseases, developed under the company's Wyeth collaboration.Trubion's product pipeline also includes Trubion's proprietary productcandidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cellmalignancies that is currently in Phase 1/2 clinical evaluation. In additionto Trubion's current clinical stage product pipeline, the company is alsodeveloping additional product candidates that build on its product developmentexperience. More information is available in the investors section ofTrubion's website: http://investors.trubion.com.

TRBN-GContact: Jim DeNike Senior Director, Corporate Communications Trubion Pharmaceuticals Inc. (206) 838-0500 jdenike@trubion.com http://www.trubion.com Waggener Edstrom Worldwide Healthcare Colleen Beauregard Senior Vice President (617) 576-5790 colleenb@waggeneredstrom.com

SOURCE Trubion Pharmaceuticals Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook